Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month High – What’s Next?

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) hit a new 52-week high during trading on Tuesday. The stock traded as high as $128.35 and last traded at $127.55, with a volume of 58,059 shares trading hands. The stock had previously closed at $128.01.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HALO. Zacks Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. HC Wainwright raised their price target on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Wells Fargo & Company raised their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Finally, Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $99.55.

Halozyme Therapeutics Trading Down 0.2%

The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market capitalization of $14.50 billion, a P/E ratio of 38.17, a P/E/G ratio of 0.47 and a beta of 0.88. The business’s fifty day simple moving average is $111.72 and its two-hundred day simple moving average is $82.31.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $82,482,605.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the sale, the director owned 58,839 shares of the company’s stock, valued at $6,339,313.86. This represents a 24.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock worth $13,538,046 over the last three months. Company insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HALO. Horizon Investment Services LLC bought a new stake in Halozyme Therapeutics in the second quarter valued at about $2,254,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Halozyme Therapeutics in the second quarter worth about $1,025,000. WINTON GROUP Ltd lifted its stake in Halozyme Therapeutics by 704.6% during the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock worth $4,723,000 after purchasing an additional 52,848 shares during the period. Great Lakes Advisors LLC bought a new position in Halozyme Therapeutics during the second quarter worth about $2,821,000. Finally, Chase Investment Counsel Corp bought a new position in Halozyme Therapeutics during the second quarter worth about $2,035,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.